Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (GB:0QZU)
LSE:0QZU
RESEARCH TOOLSreports
Vertex Pharmaceuticals (0QZU) Share Price & Analysis
9 Followers
0QZU Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$320.13 - $446.29
Previous Close$401.86
Volume678.00
Average Volume (3M)2.64K
Market Cap
$103.60B
Enterprise Value$93.11B
Total Cash (Recent Filing)$11.22B
Total Debt (Recent Filing)$724.70M
Price to Earnings (P/E)28.9
Beta0.50
Next Earnings
May 06, 2024EPS Estimate
$4.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.89
Shares Outstanding258,307,816
10 Day Avg. Volume752
30 Day Avg. Volume2,638
Standard Deviation0.08
R-Squared0.05
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)6.61
Price to Sales (P/S)6.08
Price to Cash Flow (P/CF)110.20
P/FCF Ratio188.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.43
Enterprise Value/Gross Profit10.82
Enterprise Value/Ebitda27.51
Forecast
1Y Price Target
$455.06Price Target Upside13.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering25
Vertex Pharmaceuticals News
PremiumStock Analysis & Ideas
CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
Bulls Say, Bears Say
Bulls Say
Financial GuidanceVRTX has a history of guiding well, which might lead to another small beat and raise story for this quarter's financial results, reflecting the company's consistent financial performance.
Product PipelineInvestor focus on VRTX's pipeline, including pain assets and potential data catalysts for diabetes cell therapy drug device combo, highlights the company's progress in product diversification and innovation.
Strategic AcquisitionsThe recent agreement by Vertex to acquire Alpine Immune Sciences, with its lead asset showing potentially best-in-class data, suggests a strategic enhancement to Vertex’s portfolio and a competitive advantage in the market.
Bears Say
Drug Sales And Revenue ExpectationsInitial uptake of Casgevy could take time, with adjusted sales expectations significantly lower than previous estimates.
Pipeline ConcernsStudy of VX-880 is on pause due to two deaths deemed unrelated to the treatment, but the pause may impact investor sentiment.
Product Differentiation And Market AdoptionPain is very different than rare disease... Converting a generic market to a branded one with a product that isn't differentiated on efficacy... is not going to be easy or fast (or possible at all, in some investors' opinions).
---
Options Prices
Currently, No data available
---
Ownership Overview
1.07% Insiders
52.29% Mutual Funds
28.39% Other Institutional Investors
18.25% Public Companies and
Individual Investors
0QZU FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest share price was $320.13 and its highest was $446.29 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Currently, no data Available
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is May 06, 2024 which is tomorrow.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on Feb 05, 2024. The company reported $4.2 earnings per share for the quarter, beating the consensus estimate of $4.067 by $0.133.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is $4.08.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 258,307,830 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of $4.2 in its last earnings report, beating expectations of $4.067. Following the earnings report the stock price went down -3.463%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Among the largest hedge funds holding Vertex Pharmaceuticals’s share is Bridgewater Associates, LP. It holds Vertex Pharmaceuticals’s shares valued at 54M.
---
Vertex Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$455.06 (13.24% Upside)
$455.06 (13.24% Upside)
Blogger Sentiment
Bullish
GB:0QZU Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.79%
12-Months-Change
Fundamentals
Return on Equity
22.99%
Trailing 12-Months
Asset Growth
27.19%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
---
0QZU Company Deck
---
0QZU Earnings Call
Q4 2024
0:00 / 0:00
---
0QZU Revenue Breakdown
90.63% TRIKAFTA/KAFTRIO
4.82% KALYDECO
3.30% ORKAMBI
1.25% SYMDEKO/SYMKEVI
---
0QZU Stock 12 Months Forecast
Average Price Target
$455.06
▲(13.24% Upside)
Technical Analysis
Best Analysts Covering 0QZU
1 Year
1 Year Success Rate
19/20 ratings generated profit
1 Year Average Return
+32.31%
reiterated a sell rating 24 days ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +32.31% per trade.
---